JP2008507529A5 - - Google Patents

Download PDF

Info

Publication number
JP2008507529A5
JP2008507529A5 JP2007522656A JP2007522656A JP2008507529A5 JP 2008507529 A5 JP2008507529 A5 JP 2008507529A5 JP 2007522656 A JP2007522656 A JP 2007522656A JP 2007522656 A JP2007522656 A JP 2007522656A JP 2008507529 A5 JP2008507529 A5 JP 2008507529A5
Authority
JP
Japan
Prior art keywords
composition
receptor
antibody
intended
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007522656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507529A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/025588 external-priority patent/WO2006014646A2/en
Publication of JP2008507529A publication Critical patent/JP2008507529A/ja
Publication of JP2008507529A5 publication Critical patent/JP2008507529A5/ja
Pending legal-status Critical Current

Links

JP2007522656A 2004-07-22 2005-07-20 抗サイトカインレセプター抗体を用いる診断のための方法 Pending JP2008507529A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59040004P 2004-07-22 2004-07-22
PCT/US2005/025588 WO2006014646A2 (en) 2004-07-22 2005-07-20 Methods for diagnosis using anti-cytokine receptor antibodies

Publications (2)

Publication Number Publication Date
JP2008507529A JP2008507529A (ja) 2008-03-13
JP2008507529A5 true JP2008507529A5 (OSRAM) 2008-09-11

Family

ID=35787681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007522656A Pending JP2008507529A (ja) 2004-07-22 2005-07-20 抗サイトカインレセプター抗体を用いる診断のための方法

Country Status (7)

Country Link
US (1) US7727528B2 (OSRAM)
EP (1) EP1781818B1 (OSRAM)
JP (1) JP2008507529A (OSRAM)
AU (1) AU2005269820B2 (OSRAM)
CA (1) CA2574496C (OSRAM)
DK (1) DK1781818T3 (OSRAM)
WO (1) WO2006014646A2 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315656D0 (en) * 2003-07-03 2003-08-13 Oxonica Ltd Metal oxide formulations
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
TWI617576B (zh) 2007-05-21 2018-03-11 艾爾德生物控股有限責任公司 介白素-6(il-6)的抗體及其等之用途
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
CN101868477A (zh) * 2007-05-21 2010-10-20 奥尔德生物制药公司 新型兔抗体人源化方法和人源化的兔抗体
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8058204B2 (en) * 2008-10-24 2011-11-15 GM Global Technology Operations LLC Method for generating a shell of noble metal overlaid on a core of non-noble metal, and catalysts made thereby
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
DK2406636T3 (en) 2008-12-10 2019-02-18 Joslin Diabetes Center Inc PROCEDURES FOR DIAGNOSTICATION AND PREVENTION OF RENAL DISEASE
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504030A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP
EP2643016A2 (en) 2010-11-23 2013-10-02 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
EP3097420A4 (en) * 2014-01-24 2018-01-17 Ntercept, LLC Methods and compositions for immune dis-inhibition
KR102510540B1 (ko) 2014-10-03 2023-03-16 나노틱스 엘엘씨 가용성 생물분자의 생물학적 활성을 억제하기 위한 조성물 및 방법
CN116999396A (zh) 2015-07-29 2023-11-07 纳米提克斯有限责任公司 用于清除可溶性生物分子的模块化组合物及其相关方法
EP3374399A1 (en) * 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition and methods for anti-tnfr2 antibodies
JP2019527192A (ja) 2016-05-31 2019-09-26 カーディオバックス リミテッド ライアビリティ カンパニー 全身性エリテマトーデスの診断及び治療方法
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
EP3565604A4 (en) 2017-01-04 2020-09-09 Nanotics, LLC ELIMINATING PARTICLE ASSEMBLY PROCESSES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
JPH0630788A (ja) 1992-07-16 1994-02-08 Otsuka Pharmaceut Co Ltd ヒトインターロイキン−1に対する組換え抗体
US20030138426A1 (en) * 1997-10-21 2003-07-24 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US20020039764A1 (en) 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
CN1981868A (zh) 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗-cd20在b细胞淋巴瘤治疗中的联合应用
WO2003048317A2 (en) * 2001-11-30 2003-06-12 Children's Hospital Medical Center Antibodies to magmas and uses thereof
US20040072237A1 (en) 2001-12-26 2004-04-15 Barry Schweitzer Use of cytokines secreted by dendritic cells
WO2005107802A2 (en) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients

Similar Documents

Publication Publication Date Title
JP2008507529A5 (OSRAM)
JP2009539841A5 (OSRAM)
JP2009518447A5 (OSRAM)
ES2197912T3 (es) Utilizacion de anticuerpos anti-tnf en la preparacion de medicamentos para tratar enfermedades con porcentaje serico elevado de interleucina-6.
CN1191850C (zh) 使用抗cd20嵌合抗体治疗循环肿瘤细胞相关的血液恶性肿瘤
JP2019178142A5 (OSRAM)
Rogers et al. Myelopathy in Sjögren’s syndrome: role of nonsteroidal immunosuppressants
JP2009518441A5 (OSRAM)
WO2002096461A1 (en) Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
RU2014105496A (ru) Способы снижения числа эозинофилов
Kaipiainen‐Seppänen et al. Treatment of reactive arthritis with infliximab
DE05075555T1 (de) Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
Tato et al. Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab
JP2010509234A5 (OSRAM)
JP2003501401A5 (OSRAM)
JP2019501206A5 (OSRAM)
Naniwa et al. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still’s disease
Elliott et al. Anti-cytokine therapy in rheumatoid arthritis
Bresnihan The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
JP2006528627A5 (OSRAM)
RU2009103429A (ru) Композиция для модулирования экспрессии молекул клеточной адгезии
IL307751B1 (en) Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
RU2004137823A (ru) Терапевтическое средство против гиперкальциемического криза
JP2006514681A5 (OSRAM)
SK287522B6 (sk) Použitie inhibítorov produkcie a/alebo účinku IL-18